Pharmosa Biopharm Inc.(TW:6875)
NT$25.25+0.20 (+0.80%)
TW:6875
Pharmosa Biopharm Inc. financials statements
NT$25.25
At close:+0.20 (+0.80%)
Pharmosa Biopharm Inc. (6875) Ratios
Pharmosa Biopharm Inc. Ratios
TW:6875's free cash flow for Q2 2026 was NT$-79.74M. For the 2026 fiscal year, TW:6875's free cash flow was decreased by NT$-22.29M and operating cash flow was NT$-57.45M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.11 | 14.48 | 13.02 | 24.65 | 14.39 |
| Quick Ratio | 11.91 | 14.27 | 12.74 | 24.65 | 14.39 |
| Cash Ratio | 6.35 | 6.45 | 12.56 | 24.22 | 13.95 |
| Solvency Ratio | -1.85 | -0.62 | 0.16 | -6.64 | -4.45 |
| Operating Cash Flow Ratio | -3.59 | -1.10 | 0.55 | -9.30 | -7.18 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 33.61 | -73.30 | -28.18 |
| Net Current Asset Value | NT$ 1.01B | NT$ 1.46B | NT$ 814.12M | NT$ 646.20M | NT$ 421.03M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.05 | 0.11 | 0.03 | 0.06 |
| Debt-to-Equity Ratio | 0.06 | 0.06 | 0.13 | 0.03 | 0.07 |
| Debt-to-Capital Ratio | 0.06 | 0.06 | 0.11 | 0.03 | 0.07 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Financial Leverage Ratio | 1.12 | 1.12 | 1.17 | 1.05 | 1.10 |
| Debt Service Coverage Ratio | -176.84 | -58.84 | 8.41 | -61.61 | -25.32 |
| Interest Coverage Ratio | -191.84 | -90.35 | -0.99 | -409.64 | -210.27 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.79 | 0.95 | 1.30 | 0.22 | 0.44 |
| Net Debt to EBITDA | 1.43 | 4.50 | -23.96 | 2.53 | 1.74 |
| Profitability Margins | |||||
| Gross Profit Margin | -23.41% | 75.73% | 100.00% | 0.00% | 0.00% |
| EBIT Margin | -598.88% | -99.17% | 3.60% | 0.00% | 0.00% |
| EBITDA Margin | -552.08% | -83.77% | 11.01% | 0.00% | 0.00% |
| Operating Profit Margin | -598.88% | -130.43% | -0.90% | 0.00% | 0.00% |
| Pretax Profit Margin | -570.63% | -99.45% | 2.69% | 0.00% | 0.00% |
| Net Profit Margin | -570.63% | -99.45% | 2.69% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -570.63% | -99.45% | 2.69% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 95.28% | 76.25% | -299.43% | 100.24% | 100.48% |
| Return on Assets (ROA) | -21.95% | -7.70% | 0.63% | -33.34% | -43.74% |
| Return on Equity (ROE) | -24.64% | -8.60% | 0.74% | -35.02% | -48.26% |
| Return on Capital Employed (ROCE) | -24.43% | -10.67% | -0.22% | -34.46% | -46.14% |
| Return on Invested Capital (ROIC) | -24.16% | -10.58% | -0.22% | -33.98% | -44.90% |
| Return on Tangible Assets | -21.97% | -7.70% | 0.63% | -33.35% | -43.75% |
| Earnings Yield | -5.73% | -2.49% | 0.09% | -4.26% | -6.26% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.54 | 22.55 | 213.65 | 0.00 | 0.00 |
| Payables Turnover | 10.21 | 60.07 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 4.19 | 1.64 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.15 | 0.43 | 1.74 | 0.00 | 0.00 |
| Asset Turnover | 0.04 | 0.08 | 0.24 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.05 | 0.13 | 0.40 | 0.00 | 0.00 |
| Cash Conversion Cycle | 99.73 | 232.18 | 1.71 | 0.00 | 0.00 |
| Days of Sales Outstanding | 48.40 | 16.19 | 1.71 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 87.09 | 222.07 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 35.76 | 6.08 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 135.49 | 238.26 | 1.71 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.77 | -1.01 | 0.37 | -2.56 | -2.73 |
| Free Cash Flow Per Share | -3.69 | -2.32 | -0.34 | -2.67 | -2.76 |
| Dividend Paid and CapEx Coverage Ratio | -3.00 | -0.77 | 0.52 | -25.35 | -73.12 |
| Capital Expenditure Coverage Ratio | -3.00 | -0.77 | 0.52 | -25.35 | -73.12 |
| Operating Cash Flow Coverage Ratio | -3.59 | -1.08 | 0.29 | -12.19 | -6.40 |
| Operating Cash Flow to Sales Ratio | -5.31 | -0.76 | 0.13 | 0.00 | 0.00 |
| Free Cash Flow Yield | -7.12% | -4.38% | -0.40% | -4.29% | -5.88% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -17.47 | -40.08 | 1168.67 | -23.44 | -15.99 |
| Price-to-Sales (P/S) Ratio | 99.61 | 39.91 | 31.43 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.30 | 3.45 | 8.69 | 8.22 | 7.71 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -14.05 | -22.82 | -253.15 | -23.30 | -17.02 |
| Price-to-Operating Cash Flow Ratio | -18.74 | -52.59 | 233.00 | -24.22 | -17.25 |
| Price-to-Earnings Growth (PEG) Ratio | -0.14 | 0.02 | -11.37 | 2.38 | -0.31 |
| Enterprise Value Multiple | -16.61 | -43.14 | 261.43 | -21.81 | -15.04 |
| Enterprise Value | 6.17B | 6.06B | 9.05B | 5.61B | 3.67B |
| EV to EBITDA | -16.61 | -43.14 | 261.43 | -21.81 | -15.04 |
| EV to Sales | 91.71 | 36.14 | 28.79 | 0.00 | 0.00 |
| EV to Free Cash Flow | -12.94 | -20.66 | -231.90 | -20.88 | -15.26 |
| EV to Operating Cash Flow | -17.26 | -47.62 | 213.44 | -21.70 | -15.46 |
| Tangible Book Value Per Share | 12.06 | 15.32 | 10.05 | 7.55 | 6.10 |
| Shareholders’ Equity Per Share | 12.07 | 15.33 | 10.05 | 7.56 | 6.10 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.52 | 1.33 | 2.78 | 0.00 | 0.00 |
| Net Income Per Share | -2.97 | -1.32 | 0.07 | -2.65 | -2.94 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.95 | 1.00 | 0.75 | 0.99 | 1.00 |
| Research & Development to Revenue | 5.45 | 1.76 | 0.88 | 0.00 | 0.00 |
| SG&A to Revenue | 0.30 | 0.30 | 0.13 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.04 | 0.02 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.93 | 0.76 | 5.02 | 0.97 | 0.93 |
Currency in TWD
